多奈哌齐联合醒智散治疗阿尔茨海默病的疗效分析

Analysis of the effect of donepezil combined with Xingzhisan in the treatment of Alzheimer’s disease

目的探讨多奈哌齐联合醒智散治疗阿尔茨海默病的疗效。方法 100例阿尔茨海默病患者,随机分为研究组和对照组,每组50例。两组患者均采用多奈哌齐治疗,研究组患者在此基础上联合醒智散治疗。比较两组治疗前后血清炎症因子水平、简易精神状态评价量表(MMSE)评分及临床疗效、治疗期间不良反应发生情况。结果治疗后,研究组患者白细胞介素-1β(IL-1β)为(0.23±0.07)ng/L、白细胞介素-6(IL-6)为(60.34±7.42)ng/L及肿瘤坏死因子-α(TNF-α)水平为(1360.83±490.28)ng/L,均低于对照组的(0.46±0.11)、(105.36±73.52)、(1860.53±430.87)ng/L,差异具有统计学意义(P<0.05)。治疗后,研究组患者MMSE评分(22.83±2.08)分高于对照组的(19.05±1.67)分,差异具有统计学意义(P<0.05)。研究组患者治疗总有效率为80%高于对照组的62%,差异具有统计学意义(P<0.05)。研究组患者治疗期间不良反应发生率为4%,对照组患者治疗期间不良反应发生率为6%,两组比较差异无统计学意义(P>0.05)。结论多奈哌齐联合醒智散治疗阿尔茨海默病具有较好的疗效,同时药物服用期间安全性好,对降低血清炎症因子水平有积极作用。

Objective To discuss the efficacy of donepezil combined with Xingzhisan in the treatment of Alzheimer’s disease. Methods A total of 100 patients with Alzheimer’s disease were randomly divided into research group and control group, with 50 cases in each group. Both groups were treated by donepezil, and the research group was also treated by Xingzhisan. The serum inflammatory factors level and mini-mental state examination(MMSE) score before and after treatment, clinical efficacy, and occurrence of adverse reactions during treatment were compared between the two groups. Results After treatment, the levels of interleukin-1β(IL-1β)(0.23±0.07) ng/L, interleukin-6(IL-6)(60.34±7.42) ng/L and tumor necrosis factor-α(TNF-α)(1360.83±490.28) ng/L of the research group were lower than those of the control group(0.46±0.11),(105.36±73.52) and(1860.53±430.87)ng/L, and the difference was statistically significant(P<0.05). After treatment, MMSE score(22.83±2.08) points of the research group was higher than that of the control group(19.05±1.67) points, and the difference was statistically significant(P<0.05). The total effective rate of treatment 80% of the research group was higher than that of the control group 62%, and the difference was statistically significant(P<0.05). The incidence of adverse reactions during treatment of the research group was 4%, which was 6% of the control group, and the difference was not statistically significant(P>0.05). Conclusion Donepezil combined with Xingzhisan has a good efficacy on Alzheimer’s disease. Meanwhile, it has a good safety and has a positive effect on reducing the level of serum inflammatory factors.